"Myopia God Pharmaceutical" suspended online sales experts: The short -term performance of related companies is affected

Zhongxin Jingwei, July 23 (Zhang Yan) On the 22nd, Shenyang Xingqi Ophthalmology Hospital issued a notice through the Internet Hospital Mini Program Platform stating that starting from that day, Internet hospitals have suspended 0.01%sulfuric sulfate eye drops of 0.01%of the internal preparations. It can be prescribed by Xingqi Ophthalmology Hospital.

What impact will be suspended on online sales

In October 2021, the National Health and Health Commission issued the "Advanced Technical Guide to Children and Adolescents (Update)" (referred to as the "Guide") that it was suggested to go to regular medical institutions to use Adop eye drops under the guidance of a doctor.

In fact, in addition to Xingqi Ophthalmology Hospital, there are many eye medicine companies such as El Ophthalmology, Opangshi, and He's Ophthalmology. Against the background of the market's increase in the demand for myopia, Atropine's eye drops have indeed provided considerable income for some pharmaceutical companies.

Shenyang Xingqi Eye Hospital is a wholly -owned subsidiary of Xingqi Eye Medicine. According to Xingqi Eye Pharmaceutical Financial Report, from 2019 to 2021, the company's net profit attributable to the company was 162.79%, 145.11%, and 121.31%, respectively. The fastest -growing medical service sector revenue is derived from Xingqi Ophthalmology Hospital, and 80 % of the income of the latter comes from Atropine's eye drops. Xie Login, a senior investment consultant of Jufeng Investment Consultant, said, "From 2019 to 2021, the optical diagnosis and treatment are one of the main sources of income from the company. From January to July 2021, Xingqi Ophthalm Hospital's sulfate Attot eye drops are located The pharmaceutical income sector accounts for about 97%of the entire vision diagnosis and treatment income. The suspension of sales will have a significant impact on the income of the ophthalmology hospital, which will also affect the performance income of the listed company's rejuvenation of the eye medicine. ","

Zhao Xilong, a senior investment consultant of Jufeng Investment Consultant, believes that the Guide is suitable for various types of medical institutions. Xingqi Eye medicine actively suspended the Internet to sell the seller of Eto Sulfate Eye Drops. "At present, a sales channel is suspended instead of stopping selling such products in the whole face. There may be some impact in the short -term marketing method. The sales volume will increase, and the profit impact on the enterprise is relatively limited. "

According to media reports, the customer service staff of El Ophtoba Eto Dripping said that the concentration of Attoppin eye drops of El Ophthalmology is 0.05%, which can still be mailed for the time being.

Xie Qin pointed out that low -concentration Atto is one of the few means on the market that can prevent myopia. The incidence of adolescent myopia has increased year by year, and the demand for this product has also increased rapidly. Related companies have also aimed at this huge market to start fierce competition.

How much can prevent myopia from preventing myopia

In recent years, research institutions represented by the Singapore National Ophthalmology Research Institute believe that low-concentration Atto (0.01%-0.1%) can inhibit the growth of eye axis caused by myopia, thereby delaying excessive progress of myopia. Not completely clear, there are also controversy in the medical community.

Studies have found that the control effect of Atropine on the development of myopia has a dose dependence effect. Generally speaking, the greater the dose, the relatively better the effect. However, high -concentration Atropine will have a longer durable pupil effect, resulting in patients who are afraid of light after medication, and things that look at things, especially when you look at things, are unclear. The concentration of 0.01%is relatively suitable, which can control the development of myopia to a certain extent, but also reduces side effects to very low.

Internationally, the use of Atropine's eye drops to control myopia for nearly 20 years, and it is confirmed that 0.01%of the efficiency of Acerin control in myopia can reach 30%to 50%. On July 3rd, the "Guidelines for the Prevention and Control of Children's Children's Paths" issued by the National Health and Health Commission also pointed out that low -concentration Atropine drops can be used as effective intervention measures for children's adolescent myopia development.

At present, there is no official listing product in the domestic low -concentration of Atropine's eye drops, but Adoppin is not new as an internal preparation application. In recent years, the state has approved a number of private ophthalmology hospitals to listed in low -concentration Atto internal preparations.

Jiang Han, a senior researcher at Pangu Think Tank, said that the lack of sales and sales channels for the performance effect of the performance of corporate companies related to Atto will be a normal phenomenon. In the future, related companies should further broaden sales channels and further enhance market competitiveness. (Zhongxin Jingwei APP)

This article is original by the Sino -Singapore Jingwei Research Institute, and the copyright of the Sino -Singapore Jingwei. Without written authorization, no unit or individual may be reprinted, extract or use in other ways.

Editor in charge: Sun Qingyang

Pay attention to the official WeChat public account of JWVIEW (JWVIEW) to get more elite financial information.

- END -